1. 806 Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer. (9th November 2020) Authors: Manso, Luis; Villagrasa, Patricia; Chic, Nuria; Bermejo, Begoña; Cejalvo, Juan; Izarzugaza, Yann; Cantos, Blanca; Blanch, Salvador; Margeli, Mireia; Alonso, Jose; Martínez, Alejandro; Villanueva, Rafael; Guerra, Juan; Andrés, Raquel; Zamora, Pilar; Nogales, Esteban; Juan, Manel; Gonzalez-Farre, B... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A855 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 806 Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer. (9th November 2020) Authors: Manso, Luis; Villagrasa, Patricia; Chic, Nuria; Bermejo, Begoña; Cejalvo, Juan; Izarzugaza, Yann; Cantos, Blanca; Blanch, Salvador; Margeli, Mireia; Alonso, Jose; Martínez, Alejandro; Villanueva, Rafael; Guerra, Juan; Andrés, Raquel; Zamora, Pilar; Nogales, Esteban; Juan, Manel; Gonzalez-Farre, B... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A482 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Issue 11 (November 2020) Authors: Prat, Aleix; Guarneri, Valentina; Paré, Laia; Griguolo, Gaia; Pascual, Tomás; Dieci, Maria V; Chic, Núria; González-Farré, Blanca; Frassoldati, Antonio; Sanfeliu, Esther; Cejalvo, Juan M; Muñoz, Montserrat; Bisagni, Giancarlo; Brasó-Maristany, Fara; Urso, Loredana; Vidal, Maria; Brandes, Alba A; ... Journal: Lancet oncology Issue: Volume 21:Issue 11(2020) Page Start: 1455 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Issue 3 (March 2023) Authors: Tolaney, Sara M; Tarantino, Paolo; Graham, Noah; Tayob, Nabihah; Parè, Laia; Villacampa, Guillermo; Dang, Chau T; Yardley, Denise A; Moy, Beverly; Marcom, P Kelly; Albain, Kathy S; Rugo, Hope S; Ellis, Matthew J; Shapira, Iuliana; Wolff, Antonio C; Carey, Lisa A; Barroso-Sousa, Romualdo; Villagra... Journal: Lancet oncology Issue: Volume 24:Issue 3(2023) Page Start: 273 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Age-Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older Women. (20th August 2014) Authors: Jenkins, Emily O.; Deal, Allison M.; Anders, Carey K.; Prat, Aleix; Perou, Charles M.; Carey, Lisa A.; Muss, Hyman B. Journal: Oncologist Issue: Volume 19:Number 10(2014) Page Start: 1076 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Age‐Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older Women. (20th August 2014) Authors: Jenkins, Emily O.; Deal, Allison M.; Anders, Carey K.; Prat, Aleix; Perou, Charles M.; Carey, Lisa A.; Muss, Hyman B. Journal: Oncologist Issue: Volume 19:Number 10(2014) Page Start: 1076 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Issue 4 (April 2021) Authors: Rugo, Hope S; Lerebours, Florence; Ciruelos, Eva; Drullinsky, Pamela; Ruiz-Borrego, Manuel; Neven, Patrick; Park, Yeon Hee; Prat, Aleix; Bachelot, Thomas; Juric, Dejan; Turner, Nicholas; Sophos, Nickolas; Zarate, Juan Pablo; Arce, Christina; Shen, Yu-Ming; Turner, Stuart; Kanakamedala, Hemanth; H... Journal: Lancet oncology Issue: Volume 22:Issue 4(2021) Page Start: 489 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Issue 6 (June 2021) Authors: Pérez-García, José Manuel; Gebhart, Geraldine; Ruiz Borrego, Manuel; Stradella, Agostina; Bermejo, Begoña; Schmid, Peter; Marmé, Frederik; Escrivá-de-Romani, Santiago; Calvo, Lourdes; Ribelles, Nuria; Martinez, Noelia; Albacar, Cinta; Prat, Aleix; Dalenc, Florence; Kerrou, Khaldoun; Colleoni, Mar... Journal: Lancet oncology Issue: Volume 22:Issue 6(2021) Page Start: 858 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. (January 2023) Authors: Falato, Claudette; Schettini, Francesco; Pascual, Tomás; Brasó-Maristany, Fara; Prat, Aleix Journal: Cancer treatment reviews Issue: Volume 112(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Clinical implications of the intrinsic molecular subtypes of breast cancer. (1st November 2015) Authors: Prat, Aleix; Pineda, Estela; Adamo, Barbara; Galván, Patricia; Fernández, Aranzazu; Gaba, Lydia; Díez, Marc; Viladot, Margarita; Arance, Ana; Muñoz, Montserrat Journal: Breast Issue: Volume 24(2015)Supplement 2 Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗